Colin Vale, MD

Final remarks and presentation of awards.

Experts discuss the Phase 2 D-ALBA trial results examining combination of dasatinib plus blinatumomab as frontline therapy for adults with Philadelphia chromosome-positive B cell acute lymphoblastic leukemia.

Experts provide extended follow-up on efficacy and safety outcomes with initial therapy combining ponatinib and hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Experts present findings on blinatumomab consolidation therapy from the Phase 3 ECOG-ACRIN E1910 trial in adult patients with newly diagnosed B-lineage acute lymphoblastic leukemia who achieved measurable residual disease-negative remission.

Experts provide the first report of results from the Phase 3 PhALLCON trial comparing initial therapy with ponatinib versus imatinib in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.